Genostics Company News Today

Investegate announcements from Oncimmune Hldgs PLC, Interim Results

Oncimmune Holdings FY2021 revenues of £3.7 million (over 6x increase on FY2020)

Investegate announcements from Oncimmune Hldngs PLC, Full year results and progress update

Following termination of a partnership agreement with Genostics Company, the intellectual property and distribution rights for EarlyCDT® technology in the People’s Republic of China (PRC) and Hong Kong (HK), has returned to immunodiagnostics group Oncimmune Holdings, (Nottingham, UK). Click to read more...

5 May 2021 | 09:25am StockMarketWire.com - Immunodiagnostics group Oncimmune said it had agreed to acquire the intellectual property and distribution rights for its lung-cancer diagnostics technology in China from Genostics Company. Oncimmune said the move would allow it to pursue an optimum route to market in an important territory. It had granted Genostics the exclusive rights to its EarlyCDT products. All material, IP, data, and goodwill would now be transferred back to Oncimmune, which woul...

A glance at some of the days highlights from the Proactive Investors newswire

Genostics remains Oncimmunes exclusive partner in China and continues to work closely with Oncimmune to gain market entry